DOAC does not prevent cognitive decline in adults with AF an

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
Heart Matters
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
Heart Matters
Acoramidis reduces all-cause mortality in ATTR-CM
- Daniel Judge, MD
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Heart Matters
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
- Chisato Izumi, MD, PhD
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
Heart Matters
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil

DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke